CD8A and neoplasm: Subcutaneously injected RBC vaccines can be taken up by DCs, contributing to the increased infiltration of tumour CD8+ cells, significantly enhancing the efficacy of αPD-1 therapy, and inducing a shift from CD8+ T cells to regulatory T cells.